PRNAF
ALTERITY THERAPEUTICS LTDPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 22 Alterity Therapeutics presented new Phase 2 trial data for its drug…
- R Apr 27 Alterity Therapeutics announced positive FDA feedback on the chemist…
- R Jun 9 Alterity Therapeutics announced successful alignment with the FDA on…
- X Jul 15 Short interest falls 50.5% to 5.2K
- X Jul 31 Short interest falls 38.7% to 3.2K
- X Aug 14 Short interest falls 68.5% to 1.0K
- X Aug 31 Short interest jumps 169.5% to 2.7K
- X Sep 30 Short interest falls 37.3% to 1.7K
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −37.3% to 1.7K shares.
- TrendDOWNTREND
30% below its 50-day average.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $1.1M |
| Next FY | None | None | No data | $2.0M |
Short side
FINRA· Sep 30, 2026SecBot reports
14 filings · 4 bullish · 0 bearish · 10 neutral- BULLISH 6-KJun 9, 2026
Alterity Therapeutics announced successful alignment with the FDA on the pivotal Phase 3 program…
This is a significant regulatory de-risking event for a pre-revenue biotech with a clear path to NDA. Monitor for Phase 3 trial initiation by year-end 2026 and any financing activities to support…
- NEUTRAL 6-KJun 4, 2026
Alterity Therapeutics filed a 6-K confirming a 1-for-50 reverse share consolidation, effective…
This is a purely administrative corporate action with no fundamental impact. Monitor for any subsequent capital-raising announcements that often follow reverse splits, but the filing itself does not…
- NEUTRAL 6-KJun 3, 2026
Alterity Therapeutics filed a Form 6-K on June 3, 2026, solely to report a change in its…
No trading action warranted. Monitor future filings for clinical trial results or capital events that could move the stock.
- NEUTRAL 6-KMay 29, 2026
Alterity Therapeutics filed a 6-K reporting the results of its 2026 Extraordinary General Meeting…
This is a routine procedural filing with no new financial data or material corporate events. Monitor upcoming Phase 3 trial initiation for ATH434 as the next potential catalyst.
All PRNAF filing & press-release reports (14)
- 6-K reportJun 9, 2026
- 6-K reportJun 4, 2026
- 6-K reportJun 3, 2026
- 6-K reportMay 29, 2026
- 6-K reportApr 30, 2026
- 6-K reportApr 29, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 22, 2026
- 6-K reportApr 21, 2026
- 6-K reportApr 20, 2026
- 6-K reportApr 17, 2026
- 6-K reportApr 15, 2026
- 6-K reportApr 1, 2026
- 6-K reportMar 30, 2026